Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,997Revenue (TTM) $M1,117Net Margin (%)16.5Altman Z-Score3.2
Enterprise Value $M3,605EPS (TTM) $1.5Operating Margin %29.3Piotroski F-Score6
P/E(ttm)22.2Beneish M-Score-1.6Pre-tax Margin (%)24.3Higher ROA y-yY
Price/Book5.010-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsN
Price/Sales3.75-y EBITDA Growth Rate %49.2Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow46.6y-y EBITDA Growth Rate %8.9ROA % (ttm)9.5Higher Current Ratio y-yY
Dividend Yield %--PEG0.5ROE % (ttm)24.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M124ROIC % (ttm)15.9Gross Margin Increase y-yN

Gurus Latest Trades with AKRX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AKRX is held by these investors:



AKRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ABRAMOWITZ KENNETHDirector 2016-08-15Sell2,691$30.448.11view
BONACCORSI JOSEPHSr VP Gen Counsel & Secretary 2016-06-14Sell6,500$29.8410.29view
ABRAMOWITZ KENNETHDirector 2016-06-10Sell14,675$30.169.12view
KUTINSKY BRUCECOO 2016-06-09Sell142,000$31.125.75view
JOHNSON RONALD MDirector 2016-06-07Sell7,542$31.494.51view
ABRAMOWITZ KENNETHDirector 2016-06-06Sell10,900$31.374.91view
BONACCORSI JOSEPHSr VP Gen Counsel & Secretary 2016-06-03Sell90,250$31.235.38view
Tambi BrianDirector 2016-06-02Sell25,000$30.737.09view
WEINSTEIN ALAN DDirector 2016-06-02Sell50,000$30.936.4view
Silverberg Mark MExec VP, Ops Global QA&TechSrv 2015-04-21Sell29,000$55-40.16view

Press Releases about AKRX :

Quarterly/Annual Reports about AKRX:

News about AKRX:

Articles On GuruFocus.com
FPA Capital Fund Buys 2 Low in Fourth Quarter Apr 11 2017 
FPA Capital Invests in Akorn Apr 11 2017 
Akorn Confirms Discussions with Fresenius Kabi Apr 07 2017 
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP Mar 02 2017 
Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP Feb 28 2017 
John Paulson's Bargain Stock Jan 30 2017 
Casualty List Has Done Well; Here’s the Latest Jan 18 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 

More From Other Websites
4 Stocks With Strong Technical Momentum Apr 21 2017
Analyst: Akorn Could Be Sold For As Much As $34 Per Share, But There's Double-Digits Downside If... Apr 11 2017
Akorn Acquisition Talks Send Generic Drugmakers Into Orbit Apr 10 2017
Here's Why Akorn Inc. Rose as Much as 12.8% Today Apr 10 2017
Akorn Takeover Talk Unsurprising Apr 10 2017
Akorn, Inc.: Leads amongst peers with strong fundamentals Apr 10 2017
Stocks Open Higher; Analyst Note Lifts Tesla; Canada Goose Rises Apr 10 2017
The Market In 5 Minutes Apr 10 2017
[$$] Fresenius in Talks to Buy U.S. Drug Maker Akorn Apr 08 2017
Germany's Fresenius in talks to buy generic drugmaker Akorn Apr 07 2017
Akorn Confirms Discussions with Fresenius Kabi Apr 07 2017
Akorn Launches To Six-Month High On Fresenius Takeover Rumor Apr 07 2017
Why Diana Shipping, Akorn, and Granite Construction Jumped Today Apr 07 2017
ETFs with exposure to Akorn, Inc. : April 7, 2017 Apr 07 2017
Jury awards $20M in Georgia couple case's against drug maker Apr 07 2017
Akorn shares surge 20% on report Germany's Fresenius is mulling a bid Apr 07 2017
Why Valeant Just Popped Apr 07 2017
Fresenius Says It's in Talks to Buy Generic Drugmaker Akorn Apr 07 2017
Is The Market Expensive? Buffett Says No Mar 20 2017
Blog Coverage Mylan Announces Launch of Generic Version of Pfizer's Antidepressant PRISTIQ in US Mar 13 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)